Immunostimulatory activity of exopolysaccharides from probiotic Lactobacillus casei WXD030 strain as a novel adjuvant in vitro and in vivo. Issue 1 (1st January 2018)

• Record Type: Journal Article
• Authors: Xiu, Lei; Zhang, Haochi; Hu, Zhongpeng; Liang, Yanchen; Guo, Shuai; Yang, Ming; Du, Ruiping; Wang, Xiao
• Is Part Of: Food and agricultural immunology. Volume 29:Issue 1(2018)
• Page Start: 1086
• Page End: 1105
• Publication Date: 2018-01-01
• Subjects: Exopolysaccharides -- Lactobacillus casei -- adjuvant -- immune responses; Immunochemistry -- Periodicals; Food -- Analysis -- Periodicals; Immunoassay -- Periodicals; 616.079
• DOI: 10.1080/09540105.2018.1513994
• Languages: English
• ISSNs: 0954-0105

Abstract

ABSTRACT: Exopolysaccharides act as mediators of cross-talk between probiotics and the host. Here, we found that EPS derived from probiotic Lactobacillus casei WXD030 strain (L-EPS) could modulate immune responses in vitro and in vivo . L-EPS could significantly enhance the proliferation and phagocytic activity as well as induce the production of NO, TNF-α, IL-1β and IL-6 in RAW264.7 cells. Furthermore, L-EPS could induce the maturation of BMDCs. In addition, L-EPS could largely increase the titres of OVA-specific antibodies and markedly enhanced T cell proliferation. Notably, L-EPS also increased expression of IL-4 and INF-γ expression in CD4 + T cells. Consistently, when used as an adjuvant in vivo with the foot-and-mouth disease vaccine, L-EPS largely enhanced the FMDV-specific antibody production. Collectively, these results suggested that L-EPS derived from probiotic L. casei strain had adjuvant activity, which may be a safe and efficacious adjuvant candidate suitable for a wide spectrum of prophylactic and therapeutic vaccines.